Use Labeled Indications
Malaria, prevention of relapse: Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Limitation of use: Not indicated for the treatment of acute P. vivax malaria.
Hypersensitivity to tafenoquine, other 8-aminoquinolines, or any component of the formulation; G6PD deficiency or unknown G6PD status; breastfeeding when the infant is found to be G6PD deficient or if the G6PD status of the infant is unknown.
Oral: Administer with food. Swallow tablets whole; do not break, crush, or chew. If vomiting occurs ≤1 hour after dosing, repeat dose once (do not attempt re-dosing more than once).
Take with food.
Adverse events were observed in animal reproduction studies. Due to the potential for hemolytic anemia to occur in a G6PD-deficient fetus following maternal use of tafenoquine, use during pregnancy is not recommended.
Pregnancy status should be evaluated prior to therapy. When tafenoquine is used in females of reproductive potential, effective contraception should be used during therapy and for 3 months after the last dose.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.